描述

Over the past decade, invasive techniques for diagnosing and monitoring cancers are slowly being replaced by non-invasive methods such as liquid biopsy. Liquid biopsies have drastically revolutionized the field of clinical oncology, offering ease in tumor sampling, continuous monitoring by repeated sampling, devising personalized therapeutic regimens, and screening for therapeutic resistance. A study by StrategyHelix indicates that the global liquid biopsy market is expected to increase by US$ 6,579.5 百万来自 2022 到 2028, 复合年增长率为 16.1% 在预测期内.

该报告提供了该时期的最新市场规模数据 2018-2021 并预测到 2028 covering key market aspects like sales value for liquid biopsy. The global liquid biopsy market is segmented on the basis of therapy, 应用, biomarker type, 技术, 和地区. Based on therapy, the global liquid biopsy market is categorized into oncology, noninvasive prenatal testing (NIPT), 其他的 (e.g. organ transplant). The NIPT segment captured the largest share of the market in 2021. 根据应用, the global liquid biopsy market has been segmented into diagnosis, early detection/screening, monitoring, therapy guidance. The early detection/screening segment held the largest share of the global liquid biopsy market in 2021 预计在预测期内将持有其份额. By biomarker type, the global liquid biopsy market has been segmented into cell-free nucleic acids, circulating tumor cells, 其他的. 在 2021, the cell-free nucleic acids segment made up the largest share of revenue generated by the liquid biopsy market. 以技术为基础, the global liquid biopsy market is categorized into next-generation sequencing (NGS), polymerase chain reaction (PCR), 其他的. 在这些当中, the next-generation sequencing (NGS) 该部门是收入最高的部门 2021. 从地理上来说, the global liquid biopsy market has been segmented into Asia Pacific, 欧洲, 北美, 世界其他地区 (排).

The global liquid biopsy market is highly competitive. Top players covered in Global Liquid Biopsy Market Study are Adaptive Biotechnologies Corp., Agilent Technologies Inc., Amoy Diagnostics Co. 有限公司, Becton Dickinson and Company, Berry Genomics Co. 有限公司, BGI Group, Biocartis Group, Biocept Inc., Biodesix Inc., Biolidics Limited, Bio-Rad Laboratories Inc., Bio-Techne Corp., CareDx Inc., Danaher Corp., Eurofins Scientific, EXACT Sciences Corporation, Illumina Inc., 皇家飞利浦公司, Merck KGaA, Myriad Genetics Inc., NeoGenomics Laboratories Inc., OncoCyte Corporation, Oxford Nanopore Technologies Limited, Pacific Biosciences of California Inc., Qiagen N.V., Roche Holding AG, Takara Bio Inc., Thermo Fisher Scientific Inc., VolitionRx Limited.

该报告对于活跃在该行业的公司和组织来说是宝贵的资源. It provides a cohesive picture of the liquid biopsy market to help drive informed decision making for industry executives, 政策制定者, 学术的, 和分析师.

报告范围

Therapy: oncology, noninvasive prenatal testing (NIPT), 其他的 (e.g. organ transplant)
应用: diagnosis, early detection/screening, monitoring, therapy guidance
Biomarker type: cell-free nucleic acids, circulating tumor cells, 其他的
技术: next-generation sequencing (NGS), polymerase chain reaction (PCR), 其他的
地区: 亚太地区, 欧洲, 北美, 世界其他地区 (排)
考虑的年数: 本报告涵盖期间 2018 到 2028

利益相关者的主要好处

– Get a comprehensive picture of the global liquid biopsy market
– 精准定位增长领域和投资趋势

目录

部分 1. 介绍
– 研究范围
– 学习时段
– 地理范围
– 研究方法论
部分 2. Liquid biopsy market overview
部分 3. Market breakdown by therapy
– Oncology
– Noninvasive prenatal testing (NIPT)
– 其他的 (e.g. organ transplant)
部分 4. 按应用划分的市场细分
– Diagnosis
– Early detection/screening
– Monitoring
– Therapy guidance
部分 5. Market breakdown by biomarker type
– Cell-free nucleic acids
– Circulating tumor cells
– 其他的
部分 6. 按技术划分的市场细分
– Next-generation sequencing (NGS)
– Polymerase chain reaction (PCR)
– 其他的
部分 7. 按地区划分的市场细分
– 亚太地区
– 欧洲
– 北美
– 世界其他地区 (排)
部分 8. 重点企业
– Adaptive Biotechnologies Corp.
– Agilent Technologies Inc.
– Amoy Diagnostics Co., 有限公司.
– Becton, Dickinson and Company
– Berry Genomics Co., 有限公司.
– BGI Group
– Biocartis Group
– Biocept, 公司.
– Biodesix, 公司.
– Biolidics Limited
– Bio-Rad Laboratories, 公司.
– Bio-Techne Corp.
– CareDx, 公司.
– Danaher Corp.
– Eurofins Scientific
– EXACT Sciences Corporation
– Illumina, 公司.
– 皇家飞利浦公司.
– Merck KGaA
– Myriad Genetics, 公司.
– NeoGenomics Laboratories, 公司.
– OncoCyte Corporation
– Oxford Nanopore Technologies Limited
– Pacific Biosciences of California, 公司.
– Qiagen N.V.
– Roche Holding AG
– Takara Bio Inc.
– Thermo Fisher Scientific Inc.
– VolitionRx Limited
关于StrategyHelix
免责声明